⌕
Iovance Biotherapeutics · IOVA · Nasdaq
Tenet 52 · Mixed
Compare
$7.55−2.71%At closeTenet 52 · Mixed
$7.55−0.21 (−2.71%)
At close: Nov 16, 2026, 4:00 PM ET· Nasdaq · USD

Iovance Biotherapeutics (IOVA) News

What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Sources News publishers NewsHow we compute thisNot investment advice

● MarketBeatNov 16, 2026 · 10:14 ET
Iovance Biotherapeutics Targets 2027 Lung Cancer Filing as AMTAGVI Sales Climb

Iovance Biotherapeutics NASDAQ: IOVA is preparing to seek a lung cancer indication for its cell therapy AMTAGVI in 2027 while expanding its melanoma treatment network and advancing studies in earlier-stage melanoma and r…

● Seeking AlphaNov 16, 2026 · 03:22 ET
Iovance: The Lung Selloff Went Too Far For A Business Growing 77%

Iovance's Amtagvi had its best quarter, at $101.60 million, up 77%, and operating cash burn nearly stopped at -$4.47 million. Proleukin did half of the sequential jump. The lung update sank the stock 47.60% from October …

● GlobeNewsWireNov 12, 2026 · 16:05 ETCOMPANY'S OWN WORDS
Iovance Biotherapeutics to Present at Upcoming Conference

PHILADELPHIA, Nov. 12, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymph…

● PRNewsWireNov 12, 2026 · 10:00 ET
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Iovance Biotherapeutics, Inc. - IOVA

NEW YORK, Nov. 12, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Iovance Biotherapeutics, Inc. ("Iovance" or the "Company") (NASDAQ: IOVA). Such investors are advised to contact Dan…

● Zacks Investment ResearchNov 6, 2026 · 09:36 ET
IOVA Q3 Earnings Beat on Amtagvi Sales and Lower R&D Costs

Iovance beat Q3 2026 earnings and revenue estimates as Amtagvi sales top $100 million, margins improve and R&D costs decline.…

● Seeking AlphaNov 6, 2026 · 09:02 ET
Iovance Q3 Earnings: Why I'm Reiterating My Buy Call Despite Market Reaction

Iovance Biotherapeutics, Inc., delivered strong Q3 results, with revenues up ~80% YoY and gross margin rising to 60%. IOVA reaffirmed 2026 guidance of $410–$420M revenue, and maintains a robust cash position ($376M) expe…

● Seeking AlphaNov 6, 2026 · 08:30 ET
Iovance: Reset Expectations Make The Stock A Buy Again (Rating Upgrade)

Iovance Biotherapeutics, Inc. fell 46% after my downgrade to Hold in September, reflecting over-optimism in valuation. AMTAGVI's (lifileucel) melanoma launch gained momentum, but the NSCLC opportunity appeared overestima…

● Zacks Investment ResearchNov 6, 2026 · 07:25 ET
IOVA Q3 Earnings Call Highlights Amtagvi Growth and Pipeline Progress

Iovance reaffirms its 2026 revenue outlook as Q3 sales jump 80%, fueled by Amtagvi adoption, improving margins and progress in its cancer pipeline.…

● Seeking AlphaNov 5, 2026 · 16:44 ET
Iovance Biotherapeutics, Inc. (IOVA) Q3 2026 Earnings Call Transcript

Iovance Biotherapeutics, Inc. ( IOVA ) Q3 2026 Earnings Call November 5, 2026 8:30 AM EST Company Participants Jen Saunders Frederick Vogt - Interim CEO, President, General Counsel, Corporate Secretary & Director Corleen…

● MarketBeatNov 5, 2026 · 16:15 ET
Iovance Biotherapeutics Q3 Earnings Call Highlights

Iovance Biotherapeutics NASDAQ: IOVA reported record third-quarter revenue of approximately $122 million, up 80% from a year earlier, as sales of its melanoma treatment AMTAGVI surpassed $100 million in a quarter for the…

● Zacks Investment ResearchNov 5, 2026 · 09:16 ET
Iovance Biotherapeutics (IOVA) Reports Q3 Loss, Beats Revenue Estimates

Iovance Biotherapeutics (IOVA) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to a loss of $0.25 per share a year ago.…

● GlobeNewsWireNov 5, 2026 · 07:00 ETCOMPANY'S OWN WORDS
Iovance Biotherapeutics Reports Record Third Quarter 2026 Revenue of ~$122M, Business Achievements, and Corporate Updates

Total Revenue Increased  ~80% and U.S. Amtagvi Revenue Increased ~77% Year-over-Year, and Gross Margin Increased to ~60% 24.6% Objective Response Rate (ORR) in 69 Patients with Non-Squamous Metastatic Non-Small-Cell Lung…

● Zacks Investment ResearchNov 2, 2026 · 13:21 ET
Iovance Gears Up to Report Q3 Earnings: Here's What to Expect

IOVA is poised for a Q3 earnings beat as Amtagvi sales drive revenue, Proleukin adds growth and pipeline progress draws investor attention.…

● Seeking AlphaOct 29, 2026 · 13:58 ET
Iovance Biotherapeutics, Inc. (IOVA) Discusses Positive Lifileucel Data and Precision TIL Strategy in Non-small Cell Lung Cancer Transcript

Iovance Biotherapeutics, Inc. (IOVA) Discusses Positive Lifileucel Data and Precision TIL Strategy in Non-small Cell Lung Cancer Transcript…

● MarketBeatOct 29, 2026 · 13:01 ET
Iovance's Lifileucel Shows 25% Lung Cancer Response Rate, Targets 2027 FDA Filing

Iovance Biotherapeutics NASDAQ: IOVA reported updated data from its registrational IOV-LUN-202 trial of lifileucel in previously treated, non-squamous metastatic non-small cell lung cancer, outlining plans for a suppleme…

● Zacks Investment ResearchOct 29, 2026 · 11:06 ET
Iovance Biotherapeutics (IOVA) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Iovance Biotherapeutics (IOVA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.…

● GlobeNewsWireOct 29, 2026 · 07:00 ETCOMPANY'S OWN WORDS
Iovance Reports Updated IOV-LUN-202 Results and Adds Precision TIL Strategy for Second-Line Metastatic Non-Small-Cell Lung Cancer (mNSCLC)

24.6% Objective Response Rate (ORR) in 69 Patients with Non-Squamous mNSCLC, Consistent with Previously Reported Results IOV-LUN-202 Cohorts 1 and 2 Are Completing Enrollment and Support a Planned Supplemental Biologics …

● GlobeNewsWireOct 28, 2026 · 19:00 ETCOMPANY'S OWN WORDS
Iovance Biotherapeutics to Host Webcast on Positive Data for TIL Therapy in Metastatic Non-Small Cell Lung Cancer (mNSCLC) and Broader Precision Medicine Strategy

Live Webcast at 8:30 a.m. ET on Thursday, October 29, 2026 PHILADELPHIA, Oct. 28, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developin…

● Zacks Investment ResearchOct 27, 2026 · 11:01 ET
Best Momentum Stocks to Buy for October 27th

IOVA, MEI and PRMRF made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on October 27th, 2026.…

● Zacks Investment ResearchOct 27, 2026 · 07:56 ET
New Strong Buy Stocks for October 27th

NTSK, PRMRF, IOVA, CAPL and MEI have been added to the Zacks Rank #1 (Strong Buy) List on October 27th, 2026.…

● GlobeNewsWireOct 27, 2026 · 07:00 ETCOMPANY'S OWN WORDS
Iovance Biotherapeutics to Report Third Quarter 2026 Financial Results and Corporate Updates on Thursday, November 5, 2026

PHILADELPHIA, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymph…

● GlobeNewsWireOct 26, 2026 · 07:00 ETCOMPANY'S OWN WORDS
Iovance Announces Data Showing Durable Responses with Lifileucel TIL Cell Therapy in Advanced Soft Tissue Sarcomas at ESMO 2026

50% Confirmed Objective Response Rate (ORR) with All Responses Ongoing in an Oral Presentation at the European Society for Medical Oncology (ESMO) Congress 2026 Unprecedented Efficacy in Both Refractory Undifferentiated …

● GlobeNewsWireOct 23, 2026 · 10:15 ETCOMPANY'S OWN WORDS
Iovance Presents New Data at ESMO 2026 Demonstrating Deep, Durable Responses with Lifileucel TIL Cell Therapy Plus Pembrolizumab in Frontline Advanced Melanoma

62.5% Confirmed Objective Response Rate (ORR) and 29.2% Complete Response (CR) Rate in Final Phase 2 Analysis Median Overall Survival (OS) Not Reached at More than 4 Years of Median Follow-up Oral Presentation at the Eur…

● GlobeNewsWireOct 19, 2026 · 07:00 ETCOMPANY'S OWN WORDS
Iovance Highlights TIL Cell Therapy Platform Across Solid Tumors at the European Society for Medical Oncology (ESMO) Congress 2026

Iovance Advances TIL Cell Therapy into a New Chapter in Solid Tumor Treatment Two Oral Presentations to Showcase Deep, Durable Responses with TIL Cell Therapy in Frontline Melanoma and Previously Treated Soft Tissue Sarc…

No upcoming events in the feeds.

Article counts from the last market-wide feed page, across every symbol we track and not just IOVA · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.

The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.